Ainos adds exclusive patent rights and co-development of nitrogen-oxygen separation machine with TCNT

Ainos, Inc.

Third Addendum to Product Development Agreement adds nitrogen-oxygen separation machine for medical oxygen and wound healing.
TCNT grants Ainos exclusive sales rights and full patent authorization for the new machine.
Exclusive patent use fee set at $50,000/month plus 5% sales tax for one year starting October 16, 2024.
TCNT controls ~62.9% of Ainos voting power as of October 17, 2024.
Co-development scope expanded to include VELDONA drug pre-processing and manufacturing development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.